3 ms·
Yet investors and big pharma are both running away from immuno-oncology
by Kalanos 2y ago
Yet investors and big pharma are both running away from immuno-oncology
- mettamage 2y agoWhy? Do you have some sources I could dig in to?
- bitwize 2y agoThe usual reasons: prolonged treatment is more profitable than a cure.
- biofox 2y agoThis doesn't apply when talking about terminal diseases like advanced cancer. Dead patients are the least profitable of all.
- rickydroll 2y agoMy brother committed suicide last February. His death was profitable for the funeral home. Anyone who manipulates a 90-year-old grieving mother deserves burn in several circles of hell.
- adamredwoods 2y agoThis is not true at all.
- Kalanos 2y agoMy sources are leading immuno-oncology pharma R&D teams and oncology VCs as recently as this week. I am launching an immuno-oncology therapeutics company.